Erratum: MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma (Neuro-Oncology (2010) 12:2 (116-121))

A. L. Rivera; C. E. Pelloski; M. R. Gilbert; H. Colman; E. P. De La Sulman; C. Cruz; B. N. Bekele; K. D. Aldape

doi:10.1093/neuonc/noq042

Erratum: MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma (Neuro-Oncology (2010) 12:2 (116-121))

A. L. Rivera, C. E. Pelloski, M. R. Gilbert, H. Colman, E. P. De La Sulman, C. Cruz, B. N. Bekele, K. D. Aldape

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	617
Number of pages	1
Journal	Neuro-oncology
Volume	12
Issue number	6
DOIs	https://doi.org/10.1093/neuonc/noq042
State	Published - Jun 2010

ASJC Scopus subject areas

Oncology
Clinical Neurology
Cancer Research

Access to Document

10.1093/neuonc/noq042

Cite this

Rivera, A. L., Pelloski, C. E., Gilbert, M. R., Colman, H., De La Sulman, E. P., Cruz, C., Bekele, B. N., & Aldape, K. D. (2010). Erratum: MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma (Neuro-Oncology (2010) 12:2 (116-121)). Neuro-oncology, 12(6), 617. https://doi.org/10.1093/neuonc/noq042

Erratum: MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma (Neuro-Oncology (2010) 12:2 (116-121)). / Rivera, A. L.; Pelloski, C. E.; Gilbert, M. R. et al.
In: Neuro-oncology, Vol. 12, No. 6, 06.2010, p. 617.

Research output: Contribution to journal › Comment/debate › peer-review

Rivera, AL, Pelloski, CE, Gilbert, MR, Colman, H, De La Sulman, EP, Cruz, C, Bekele, BN & Aldape, KD 2010, 'Erratum: MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma (Neuro-Oncology (2010) 12:2 (116-121))', Neuro-oncology, vol. 12, no. 6, pp. 617. https://doi.org/10.1093/neuonc/noq042

@article{d07a482e07db40ef87e9df7e3caaef6f,

title = "Erratum: MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma (Neuro-Oncology (2010) 12:2 (116-121))",

author = "Rivera, \{A. L.\} and Pelloski, \{C. E.\} and Gilbert, \{M. R.\} and H. Colman and \{De La Sulman\}, \{E. P.\} and C. Cruz and Bekele, \{B. N.\} and Aldape, \{K. D.\}",

year = "2010",

month = jun,

doi = "10.1093/neuonc/noq042",

language = "English (US)",

volume = "12",

pages = "617",

journal = "Neuro-oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Erratum

T2 - MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma (Neuro-Oncology (2010) 12:2 (116-121))

AU - Rivera, A. L.

AU - Pelloski, C. E.

AU - Gilbert, M. R.

AU - Colman, H.

AU - De La Sulman, E. P.

AU - Cruz, C.

AU - Bekele, B. N.

AU - Aldape, K. D.

PY - 2010/6

Y1 - 2010/6

UR - https://www.scopus.com/pages/publications/77957085780

UR - https://www.scopus.com/inward/citedby.url?scp=77957085780&partnerID=8YFLogxK

U2 - 10.1093/neuonc/noq042

DO - 10.1093/neuonc/noq042

M3 - Comment/debate

AN - SCOPUS:77957085780

SN - 1522-8517

VL - 12

SP - 617

JO - Neuro-oncology

JF - Neuro-oncology

IS - 6

ER -

Erratum: MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma (Neuro-Oncology (2010) 12:2 (116-121))

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this